Form 10-Q · Quarterly report
Merck & Co. 10-Q, filed Aug 7, 2026
- Filed
- CIK
- 0000310158
- Accession no.
- 0000310158-26-000212
Summary
Merck & Co. reported worldwide sales of $16.6 billion for the second quarter of 2026 and $32.9 billion for the first six months, both up 5% year over year, and detailed 2026 acquisitions of TARGAN for about $650 million, Terns Pharmaceuticals for $6.8 billion, and Cidara Therapeutics for $9.2 billion.
Key points
- Merck recorded a $5.7 billion research and development charge tied to the Terns acquisition and a $9.0 billion charge tied to the Cidara acquisition in the first six months of 2026.
- MK-4208 is in a Phase 1/2 trial for Philadelphia chromosome-positive chronic myeloid leukemia, and MK-1406 is in a Phase 3 trial for influenza prevention.
- Second-quarter sales growth came from oncology, cardiometabolic and respiratory, and animal health, partially offset by declines in diabetes and infectious diseases.
- Under the Inflation Reduction Act, Januvia’s government-set price took effect on January 1, 2026, while set prices for Janumet and Janumet XR are due to take effect on January 1, 2027.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Business Development Transactions Below is a summary of significant business development activity thus far in 2026. In July 2026, Merck acquired TARGAN, a privately held company developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for approximately $650 million. The acquisition is expected to broaden Merck Animal Health’s portfolio in commercial poultry operations with WingScan, an automated solution that uses vision technology for gender identification. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.